Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network

Journal of Substance Abuse Treatment(2021)10.1016/j.jsat.2021.108489Source: DataRank Database

Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network is a research paper published in Journal of Substance Abuse Treatment (2021). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 0.95)OA: greenTopics (36)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Theresa Winhusen ORCID,Jennifer Scodes ORCID,Martina Pavlicová ORCID,Dylanne Twitty,Aimee Campbell ORCID

Live enrichment

PubMed:34118716 PMC:PMC8478713 OpenAlex:https://openalex.org/W3164393290

University of Cincinnati College of Medicine

Grant: UG1DA013732

New York University

Grant: UG1DA013035

NIDA NIH HHS

Grant: K23 DA042130

NIDA NIH HHS

Grant: U10 DA013035

NIDA NIH HHS

Grant: U10 DA013732

National Institute on Drug Abuse

National Institutes of Health

FWCI

0.95

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8478713

publisherhttps://api.elsevier.com/content/article/PII:S0740547221002154?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0740547221002154?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jsat.2021.108489

Fields of Study

Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesSmoking Behavior and CessationAdultBuprenorphineDelayed-Action PreparationsHumansInjections, IntramuscularNaltrexoneNarcotic AntagonistsOpioid-Related DisordersTobacco Use

MeSH Terms

AdultBuprenorphineDelayed-Action PreparationsHumansInjections, IntramuscularNaltrexoneNarcotic AntagonistsOpioid-Related DisordersTobacco Use

Keywords

Opioid use disorderBuprenorphineMedicineNaltrexoneSmoking cessationMethadoneSubstance abuseOpiate Substitution TreatmentRandomized controlled trialOpioidAbstinenceInternal medicinePsychiatrySmokingCigarettes

Sustainable Development Goals

SDG 0: Good health and well-being